Acquired and inherited hipercoagulability among patients with cerebral venous thrombosis;Hipercoagulabilidad hereditaria y adquirida en pacientes con trombosis venosa cerebral

Neurologia

Volumn 17, Issue 8, 2002, Pages 405-409

  Sanchez Marin B ^a   Grasa, J M ^a   Latorre, A ^a   Montanes M A ^a   Garcia Erce J A ^a   Torres, M ^a   Calvo, M T ^a   Giralt, M ^a  

^a NONE   (Spain)

Author keywords

Cerebral venous thrombosis; Hypercoagulability; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ACTIVATED PROTHROMBIN COMPLEX; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BRAIN VEIN; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DATA BASE; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; FEMALE; GENETIC DISORDER; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LEG THROMBOSIS; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PROTHROMBIN TIME; RISK FACTOR; STATISTICS;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION TESTS; CEREBRAL VEINS; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; RISK FACTORS; THROMBOPHILIA;

EID: 0036810386     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lüdemann P, Nabavi DG, Junker R, Wolff E, Papke K, Buchner H, et al. Factor V Leiden mutation ia a risk factor for cerebral venous thrombosis. Stroke 1998;29:2507-10.
2. Deschiens MA, Conrad J, Horellou MH, Ameri A, Preter M, Chendru F, et al. Coagulation studies, factor V Leiden and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-30.
3. Hillier CE, Collins PW, Bowen DJ, Bowley S, Wiles CM. Inherited prothrombotic risk factors and cerebral venous thrombosis. QJM 1998;91:677-80.
4. Biousse V, Conard J, Brouzes C, Horellou NH, Ameri A, Bousser MG. Frequency of the 20210 G→ A mutation in the 3′-untranslated region of the prothrombin gene in 35 cases of cereral venous thrombosis. Stroke 1998;29:1398-400.
5. Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Juttler E, et al. Prothrombin G20210→A transition is a risk factor for cerebral venous thrombosis. Stroke 1998;29:1765-9.
6. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997;28:2363-9.
7. Stolz E, Kemkes-Matthes B, Potzsch B, Hahn M, Kraus J, Wirbartz M. Screening for thrombophilic factors among 25 german patients with cerebral venous thrombosis. Acta Neurol Scand 2000;102:31-6.
8. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000;95:2780-5.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
10. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.
11. Van Krimpen J, Leebeek FW, Dippel DW, Gómez García E. Prothrombin gene variant (G20210A) in a patient with cerebral venous sinus thrombosis. J Clin Neurol Neurosurg 1999;101:53-5.
12. Sánchez-Marín B, Marta-Moreno E, Alarcía-Alejos R, López-Pérez A, Serrano-Ponz M, Latorre-Jimenez A. Trombosis venosa cerebral asociada a la variante G20210A del gen de la protrombina. Neurología 2000;15:473-584.
13. Verdelho A, Ferro JM, Palmeiro A, Antunes C. Trombosis venosa cerebral y mutación G20210A del gen de la protrombina familiar. Rev Neurol 2001;33:335-8.
14. Souto JC, Coll I, Llobet D, del Rio E, Oliver A, Mateo J, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998;80:366-9.
15. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
16. Moliner-Calderón E, López-Bernal E, Ginovart-Galiana G, Nadal-Amat J, Cubells-Riero J. Trombosis cerebral neonatal y déficit de factor V Leiden. An Pediatr 2000;52:52-5.
17. Bertina RM, Koeleman BPMC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:67-7.
18. Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous trombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia study. Lancet 1993;342:1503-6.
19. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-80.
20. Weih M, Mehraein S, Valdueza JM, Einhäupl KM. Coincidence of factor V Leiden mutation and a mutation in the prothrombin gene at position 20210 in a patient with puerperal cerebral venous thrombosis. Stroke 1998;29:1739-40.
21. Liu XY, Gabig TG, Bang NU. Combined heterozyosity of factor V Leiden and the G20210A prothrombin gene mutation in a patient with cerebral cortical thrombosis. Am J Hematol 2000;64:226-8.
22. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
23. Kang SS, Zhou J, Wong PW, Kowalisyn J, Stroksch G. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-21.
24. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000;96:762-4.
25. Vidailhet M, Piette JC, Wechsler B, Bousser MG, Brunet P. Cerebral venous thrombosis in systemic lupus erythematosus. Stroke 1990;21:1226-31.
26. Christopher R, Nagaraja D, Dixit NS, Narayanan CP. Anticardiolipin antibodies: A study in cerebral venous thrombosis. Acta Neurol Scand 1999;99:121-4.
27. Provenzale JM, Heinz ER, Ortel TL, Macik BG, Charles LA, Alberts MJ. Antiphospholipid antibodies in patients without systemic lupus erythematosus: Neuroradiologic findings. Radiology 1994;192:531-7.
28. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheumatism 1999;42:1309-11.
29. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Br J Haematol 2000;109:704-15.
30. Marchetti M, Pistorio A, Barosi G. Extended anticogulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 2000;84:752-7.